Pomegra
Dyne Therapeutics Stock Falls 23% on Rival Dystrophy Trial Failure
Why is Dyne Therapeutics stock down today?
Dyne Therapeutics (DYN) stock fell 23% to $18.60 on Tuesday when Novartis's rival myotonic dystrophy drug failed Phase 3, triggering a disease-class selloff and a J.P. Morgan downgrade to $10.
Key numbers
| DYN 1-Day Drop (Sep 8) | -23.4%From prior close $24.28 to close $18.60 |
|---|---|
| DYN Premarket Low (Sep 8) | $17.00~30% below prior close of $24.28 |
| J.P. Morgan Price Target | $10Cut from $17; implies >50% downside from Sep 9 price |
| Sarepta (SRPT) 1-Day Drop (Sep 8) | >-9%Sympathy selloff; no company-specific catalyst |
| PepGen (PEPG) 1-Day Drop (Sep 8) | >-5%Sympathy selloff; no company-specific catalyst |
| HARBOR Trial Enrollment | ~160 patientsFailed primary endpoint: video hand opening time vs placebo |
What happened
Dyne Therapeutics (DYN) stock fell 23% to $18.60 on Tuesday when Novartis's rival myotonic dystrophy drug failed Phase 3, triggering a disease-class selloff and a J.P. Morgan downgrade to $10. Novartis bought Avidity Biosciences for $12 billion — a deal that closed March 2, 2026 — to gain del-desiran, a drug for the rare genetic muscle-wasting condition myotonic dystrophy type 1; in the Phase 3 HARBOR study of roughly 160 patients, del-desiran failed to improve hand-opening speed over placebo. Sarepta Therapeutics (SRPT) dropped more than 9% and PepGen (PEPG) fell more than 5% in sympathy, despite neither company announcing any bad news of its own. J.P. Morgan then cut Dyne from Neutral to Underweight the next morning and slashed its price target from $17 to $10, citing elevated clinical risk across the disease class.
Why it matters
Dyne Therapeutics is now the lone front-runner in the race to treat myotonic dystrophy type 1, but rival failures in rare diseases tend to drag down every company in the category — even those with stronger early results. That is what happened to Sarepta and PepGen investors on Tuesday: real losses from someone else's setback, with no company-specific bad news to justify the fall. With Dyne's own Phase 1/2 data due at medical conferences in late September 2026, the pressure on that readout has never been higher.
Who this affects
- MarketbearishHigh impact
- Neuromuscular biotech stocks sold off broadly on DM1 class doubt.
- CompanybearishHigh impact
- Dyne faces deep investor skepticism ahead of its own DM1 data readout.
- CompetitorsbearishMedium impact
- Sarepta and PepGen lost market value despite no company-specific bad news.
- IndustrybearishHigh impact
- Myotonic dystrophy drug development credibility shaken across the entire class.
Dyne Therapeutics vs Sarepta Therapeutics, PepGen
How we got here
Novartis announces $12B deal to acquire Avidity Biosciences and del-desiran
Novartis closes Avidity acquisition; del-desiran enters Phase 3 HARBOR study
HARBOR Phase 3 fails; DYN drops 23%, SRPT falls >9%, PEPG falls >5%
J.P. Morgan cuts DYN from Neutral to Underweight, price target slashed to $10
What to watch
- Dyne's 6- and 12-month ACHIEVE Phase 1/2 data presentations at medical conferences2026-09-30
- ACHIEVE registrational cohort topline readout — Dyne's key FDA-track value catalystQ1 2027
- FDA action date for Dyne's DMD drug zeleciment rostudirsen biologics license application2027-01-21
Educational content only. Not investment advice.
More briefsAll briefs →
Roivant Sciences Stock Jumps 24% on Record PHocus Trial Result
Roivant Sciences (ROIV) shares soared as Pulmovant's mosliciguat cut PVR 56.3%, a PH-ILD trial record.
Reddit Stock Jumps 6% on Fastest User Growth of 2026
Reddit (RDDT) rose 6% Thursday as Piper Sandler data showed 18% annual user growth in August, the year's best.
Zumiez Stock Sinks 16% on Q2 Earnings Miss and Guidance Cut
Zumiez (ZUMZ) reported a Q2 loss of $0.17 per share and says Q3 sales are running 4.3% below last year.